Merck-backed nerve stimulation device producer ElectroCore has raised new funding, according to a securities filing that shows the company is seeking a $65m close.
ElectroCore, a US-based medical device developer backed by pharmaceutical firm Merck, has raised $36m in a funding round with a $65m target, according to a regulatory filing.
Founded in 2005, ElectroCore is working on therapies that use non-invasive stimulation of the vagus nerve – the body’s longest cranial nerve, which passes through the neck and thorax to the abdomen. The approach has therapeutic applications in neurological, inflammatory and metabolic conditions.
The company is initially focusing on migraines and cluster headaches,…
